American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy

Brachytherapy

Volumn 11, Issue 1, 2012, Pages 20-32

  Yamada, Yoshiya ^a   Rogers, Leland ^b   Demanes, D Jeffrey ^c   Morton, Gerard ^d   Prestidge, Bradley R ^e   Pouliot, Jean ^f   Cohen, Gil'ad N ^a   Zaider, Marco ^a   Ghilezan, Mihai ^g   Hsu, I Chow ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Gammawest Brachytherapy   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e South Texas Radiation Therapy Associates   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

American Brachytherapy Society; Guidelines; High dose rate brachytherapy; Prostate cancer

Indexed keywords

ARTICLE; BLADDER CATHETERIZATION; BRACHYTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; DOSIMETRY; ENTERITIS; HUMAN; MEDICAL HISTORY; MEDICAL SOCIETY; MONOTHERAPY; MORBIDITY; PATIENT ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DEPTH DOSE; RADIATION DOSE; RADIATION SAFETY; RECTUM FISTULA; RECTUM SURGERY; RISK ASSESSMENT; SALVAGE THERAPY; TARGET ORGAN; TOXICITY; TRANSURETHRAL RESECTION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT DISEASE;

BRACHYTHERAPY; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; UNITED STATES;

EID: 84855984259     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.09.008     Document Type: Article

References (78)

1. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
2. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71:1028-1033.
3. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
4. Morton G.C. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005, 17:219-227.
5. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
6. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048-1055.
7. Hsu I.C., Bae K., Shinohara K., et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: Preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010, 78:751-758.
8. Hoskin P.J., Motohashi K., Bownes P., et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007, 84:114-120.
9. Guedea F., Ventura M., Mazeron J.J., et al. Patterns of care for brachytherapy in Europe: Facilities and resources in brachytherapy in the European area. Brachytherapy 2008, 7:223-230.
10. Kovacs G., Melchert C., Sommerauer M., et al. Intensity modulated high-dose-rate brachytherapy boost complementary to external beam radiation for intermediate- and high-risk localized prostate cancer patients-how we do it in Lubeck/Germany. Brachytherapy 2007, 6:142-148.
11. Martinez A.A., Demanes J., Vargas C., et al. High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33:481-488.
12. Principles and practice of brachytherapy 1997, Futura Publishing Company, Armonk, NY. S. Nag (Ed.).
13. Valero J., Cambeiro M., Galan C., et al. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: Feasibility report. Int J Radiat Oncol Biol Phys 2010, 76:386-392.
14. Hsu I.C., Cabrera A.R., Weinberg V., et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachytherapy 2005, 4:202-206.
15. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005, 62:1322-1331.
16. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
17. Demanes D.J., Brandt D., Schour L., et al. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009, 32:342-347.
18. NCCN Clinical Practice Guidelines in Oncology Prostate cancer 2010, V.3.2.2010, NCCN, Available at: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
19. Futterer J.B.J. 3T MRI of prostate cancer. Appl Radiol 2009, 38:25-32.
20. Hsu I.C., Pickett B., Shinohara K., et al. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation. Int J Radiat Oncol Biol Phys 2000, 46:851-858.
21. Pieters B.R., de Back D.Z., Koning C.C., et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: A systematic review. Radiother Oncol 2009, 93:168-173.
22. Grills I.S., Martinez A.A., Hollander M., et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-1104.
23. Lee B., Shinohara K., Weinberg V., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
24. Song D.Y., Lawrie W.T., Abrams R.A., et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 2001, 51:455-459.
25. Tharp M., Hardacre M., Bennett R., et al. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 2008, 7:231-236.
26. Peddada A.V., Jennings S.B., Faricy P.O., et al. Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 2007, 178:1963-1967.
27. Monroe A.T., Faricy P.O., Jennings S.B., et al. High-dose-rate brachytherapy for large prostate volumes (> or=50cc)-Uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 2008, 7:7-11.
28. Ishiyama H., Kitano M., Satoh T., et al. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: An analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity. Int J Radiat Oncol Biol Phys 2009, 75:23-28.
29. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27:92-99.
30. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
31. McCredie M., Staples M., Johnson W., et al. Prevalence of urinary symptoms in urban Australian men aged 40-69. J Epidemiol Biostat 2001, 6:211-218.
32. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
33. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
34. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
35. Quality assurance for clinical radiotherapy treatment planning. Med Phys 1998, 25:1773. American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53.
36. Mutic S., Palta J.R., Butker E.K., et al. Quality assurance for computed-tomography simulators and the computed-tomography-simulation process: Report of the AAPM Radiation Therapy Committee Task Group No. 66. Med Phys 2003, 30:2762-2792.
37. Pfeiffer D., Sutlief S., Feng W., et al. AAPM Task Group 128: Quality assurance tests for prostate brachytherapy ultrasound systems. Med Phys 2008, 35:5471-5489.
38. Dose and volume specification for reporting interstitial therapy [Report 58]. 1997.
39. Charra-Brunaud C., Hsu I.C., Weinberg V., et al. Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high-dose-rate brachytherapy using a computer model. Int J Radiat Oncol Biol Phys 2003, 56:586-591.
40. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 1998, 41:525-533.
41. Ghadjar P., Gwerder N., Madlung A., et al. Use of gold markers for setup in image-guided fractionated high-dose-rate brachytherapy as a monotherapy for prostate cancer. Strahlenther Onkol 2009, 185:731-735.
42. DeWerd L.A., Ibbott G.S., Meigooni A.S., et al. A dosimetric uncertainty analysis for photon-emitting brachytherapy sources: Report of AAPM Task Group No. 138 and GEC-ESTRO. Med Phys 2011, 38:782-801.
43. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995, 22:209-234.
44. Cohen G.N., Amols H.I., Zaider M. An independent dose-to-point calculation program for the verification of high-dose-rate brachytherapy treatment planning. Int J Radiat Oncol Biol Phys 2000, 48:1251-1258.
45. Ouhib Z. HDR brachytherapy for prostate. Brachytherapy Physics 2005, Medical Physics Publishing Corporation, Madison, WI. B. Thomadsen, M.J. RIvard, W.M. Bulter (Eds.).
46. Kim Y., Hsu I.C., Pouliot J. Measurement of craniocaudal catheter displacement between fractions in computed tomography-based high dose rate brachytherapy of prostate cancer. J Appl Clin Med Phys 2007, 8:2415.
47. Tiong A., Bydder S., Ebert M., et al. A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible. Int J Radiat Oncol Biol Phys 2010, 76:1066-1072.
48. Yoshida K., Yamazaki H., Nose T., et al. Needle applicator displacement during high-dose-rate interstitial brachytherapy for prostate cancer. Brachytherapy 2010, 9:36-41.
49. Phan T.P., Syed A.M., Puthawala A., et al. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 2007, 177:123-127. discussion 127.
50. Deger S., Boehmer D., Roigas J., et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005, 47:441-448.
51. Ghilizen M.M.A., Gustason G., Krauss D., et al. High dose rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate risk prostate cancer: Preliminary toxicity data. Int J Radiat Oncol Biol Phys 2011.
52. Sullivan L., Williams S.G., Tai K.H., et al. Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 2009, 91:232-236.
53. Pellizzon A.C., Salvajoli J.V., Maia M.A., et al. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol 2004, 171:1105-1108.
54. Marks L.B., Carroll P.R., Dugan T.C., et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995, 31:1257-1280.
55. Luo H.L., Fang F.M., Chuang Y.C., et al. Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. BJU Int 2009, 104:1620-1623.
56. Duchesne G.M., Williams S.G., Das R., et al. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: Mature prospective phase I/II study results. Radiother Oncol 2007, 84:128-134.
57. Demanes D.J., Martinez A.A., Ghilezan M., et al. High-dose-rate monotherapy: Safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys February 2011, [Epub ahead of print].
58. Pinkawa M., Piroth M.D., Holy R., et al. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer. Radiother Oncol 2010, 96:25-29.
59. Erickson B.A., Demanes D.J., Ibbott G.S., et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:641-649.
60. Astrom L., Pedersen D., Mercke C., et al. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005, 74:157-161.
61. Chen Y.C., Chuang C.K., Hsieh M.L., et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: An experience in Taiwan. Urology 2007, 70:101-105.
62. Chin Y.S., Bullard J., Bryant L., et al. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) 2006, 18:474-479.
63. Kalkner K.M., Wahlgren T., Ryberg M., et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncol 2007, 46:909-917.
64. Kaprealian T., Weinberg V., Speight J.L., et al. High-dose-rate brachytherapy boost for prostate cancer: Comparison of two different fractionation schemes. Int J Radiat Oncol Biol Phys December 14 2010, [Epub ahead of print].
65. Morton G.C., Loblaw D.A., Sankreacha R., et al. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: Analysis of short- and medium-term toxicity and quality of life. Int J Radiat Oncol Biol Phys 2010, 77:811-817.
66. Niehoff P., Loch T., Nurnberg N., et al. Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy 2005, 4:141-145.
67. Pellizzon A.C., Nadalin W., Salvajoli J.V., et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol 2003, 66:167-172.
68. Pistis F., Guedea F., Pera J., et al. External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: The initial experience of the Catalan Institute of Oncology. Brachytherapy 2010, 9:15-22.
69. Sato M., Mori T., Shirai S., et al. High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:1002-1009.
70. Vargas C.E., Martinez A.A., Boike T.P., et al. High-dose irradiation forprostate cancer via a high-dose-rate brachytherapy boost: Results of a phase I to II study. Int J Radiat Oncol Biol Phys 2006, 66:416-423.
71. Vargas C.E., Galalae R., Demanes J., et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 2005, 63:1474-1482.
72. Wilder R.B., Barme G.A., Gilbert R.F., et al. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone. Brachytherapy 2010, 9:341-348.
73. Zwahlen D.R., Andrianopoulos N., Matheson B., et al. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy 2010, 9:27-35.
74. Jabbari S., Weinberg V.K., Shinohara K., et al. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost. Int J Radiat Oncol Biol Phys 2010, 76:36-42.
75. Rogers C.L., Alder A.S., Rogers R.L., et al. High dose rate brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol November 14, 2011, [Epub ahead of print].
76. Yoshioka Y., Konishi K., Sumida I., et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011.
77. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003, 169:974-979. discussion 979-980.
78. Hoskin P., Rojas A., Lowe G., et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys June 14 2011, [Epub ahead of print].